Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Grivas on Ongoing Trials in Advanced Bladder Cancer

July 7th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses ongoing trials in advanced bladder cancer.

Expert Elaborates on Emerging Advances in Bladder Cancer Care

July 6th 2018

Petros Grivas, MD, PhD, discusses ongoing clinical trials exploring novel approaches with the potential to change practice in advanced bladder cancer.

Expert Highlights Atezolizumab/Bevacizumab Combo in RCC

July 6th 2018

Brian I. Rini, MD, discusses atezolizumab plus bevacizumab as an effective frontline combination in renal cell carcinoma, as well as patient reported outcomes with the regimen.

Expert Shares Upfront Sequencing Strategies in mRCC

July 6th 2018

Sumanta Kumar Pal, MD, sheds light on the latest frontline therapeutic options for patients with mRCC and other advancements on the horizon.

Dr. Choueiri Discusses Checkpoint Inhibitors in RCC

July 4th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses checkpoint inhibitors in renal cell carcinoma (RCC).

Dr. Rini on the Tolerability of Atezolizumab Plus Bevacizumab in RCC

July 3rd 2018

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the tolerability of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma.

MRI Combination Techniques Hone Accuracy of Prostate Cancer Diagnosis

July 2nd 2018

Several studies presented at this year’s American Urological Association meeting underscored the value of multiparametric magnetic resonance imaging in the diagnosis and management of prostate cancer.

Dr. Galsky Discusses Combination Immunotherapy in Bladder Cancer

June 29th 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses combination immunotherapy in the treatment of patients with bladder cancer.

Dr. Siefker-Radtke on the Phase II Study of Erdafitinib in Patients With Urothelial Carcinoma

June 29th 2018

Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the phase II study of erdafitinib in patients with metastatic or unresectable urothelial carcinoma who have FGFR alterations.

Dr. Rosenberg Discusses Enfortumab Vedotin in Urothelial Carcinoma

June 28th 2018

Jonathan E. Rosenberg, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses enfortumab vedotin in patients with locally advanced or metastatic urothelial carcinoma previously treated with an immune checkpoint inhibitor.

Dr. Pal Discusses the Role of PD-L1 in Metastatic RCC

June 27th 2018

Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the role of PD-L1 in metastatic renal cell carcinoma.

Findings Set Stage for Expanded Immunotherapy Role in Bladder Cancer

June 26th 2018

Researchers now are turning their attention toward earlier disease settings involving patients who are refractory to standard therapies in nonmuscle-invasive bladder cancer or who are poor candidates for surgery in muscle-invasive bladder cancer.

Dr. Galsky Discusses the Rationale for the IMvigor130 Study in Bladder Cancer

June 23rd 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses the rationale for the IMvigor130 study in metastatic bladder cancer.

FDA Adds PD-L1 Expression to Frontline Pembrolizumab, Atezolizumab Urothelial Carcinoma Labels

June 21st 2018

The FDA has incorporated PD-L1 status into the labels for pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for existing frontline approvals for platinum-ineligible patients with urothelial carcinoma.

Dr. Rini Discusses Atezolizumab Plus Bevacizumab in RCC

June 20th 2018

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma.

Dr. Grivas on Immunotherapy in Advanced Urothelial Cancer

June 19th 2018

Agarwal Addresses Sequencing Challenges in Kidney Cancer

June 19th 2018

Neeraj Agarwal, MD, discusses his preferred sequencing strategies for treating patients with kidney cancer, and ongoing immunotherapy research in the field.

Dr. Drake Discusses the CARMENA Trial in Metastatic RCC

June 14th 2018

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the CARMENA trial in metastatic renal cell carcinoma (mRCC).

Dr. Gupta on Phase Ib/II Trial of Pembrolizumab With Bevacizumab in RCC

June 14th 2018

Shilpa Gupta, MD, assistant professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses the phase Ib/II studies of pembrolizumab with bevacizumab for the treatment of patients with metastatic renal cell carcinoma.

Dr. Rini Discusses the Findings of IMmotion151 in RCC

June 12th 2018

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses findings from the IMmotion151 trial in renal cell carcinoma.